Exploration of research projects on personalised prevention supported by the European Commission

Abstract The interaction between environmental exposures, lifestyle factors, and genetic predisposition affect individual susceptibility to chronic diseases. Personalised Prevention (PP) has emerged in the recent years as potential approach to integrate traditional public health approaches in prevention. The implementation of PP into national health systems so far has not realized its full potential due to a number of obstacles including scanty evidence from research. Within the project “PROPHET: A Map for Personalised Prevention in the Future of Healthcare”, we conducted an extensive mapping of currently active research projects in the field of PP. We carried out a scoping review according to Arksey and O’Malley methodology, followed by consultations with experts in personalised medicine and prevention. We included 45 ongoing research projects on PP, of which 57.8% were funded by Horizon Europe, 35.5% by Horizon 2020, and 6.7% by Eu4Health. Regarding disease types, 40% of the projects were about cancer, 20% on cardiovascular and 20% on neurological and psychiatric diseases, followed by metabolic diseases and other chronic conditions. Overall, the EC allocated approximately €160 million to cancer personalised prevention projects, roughly double of the funding dedicated to cardiovascular, neurological and psychiatric diseases. The emphasis on cancer projects is noteworthy, with Horizon Europe emerging as the main funding programme aligned with the ongoing Cancer Mission. Regardless of the disease, most of the projects addressed primary and secondary personalised prevention research. This is in line with the limited approaches in PP in the setting of primary and secondary personalised prevention (e.g., genetic testing to identify high risk subjects for breast cancer) compared to tertiary prevention (e.g., pharmacogenomics). This comprehensive mapping underlines the EU’s continued commitment to promoting PP, which is fundamental to the future of healthcare. Key messages • The EC prioritises significant financial resources towards cancer personalised prevention research projects, highlighting Cancer Mission as a focal initiative in the personalised prevention field. • European-funded projects focus on primary and secondary personalised prevention strategies. This suggest that we currently miss evidence in these areas.